Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms AMAC
  • Sponsors Eli Lilly and Company; Eli Lilly Japan

Most Recent Events

  • 17 Oct 2023 Results assessing the transcription profile of patients with ulcerative colitis who respond to placebo or mirikizumab versus non-responders and build a model that can predict response in patients with ulcerative colitis, presented at the 31st United European Gastroenterology Week.
  • 23 Aug 2023 Results from NCT02589665, NCT03518086 and NCT03524092, evaluating Mirikizumab pharmacokinetics in patients with Moderately to Severely Active Ulcerative Colitis, published in the Clinical Pharmacokinetics
  • 09 May 2023 Results of pooled analysis from three studies(NCT02589665, NCT03518086 and NCT03524092) assessing Mirikizumab pharmacokinetics and exposure response relationships in patients with moderately to severely active ulcerative colitis presented at the Digestive Disease Week 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top